The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model

European Journal of Pharmacology

Volumn 698, Issue 1-3, 2013, Pages 278-285

  Ponten, Henrik ^a   Kullingsjö, Johan ^a   Sonesson, Clas ^a   Waters, Susanna ^a   Waters, Nicholas ^a   Tedroff, Joakim ^a  

^a NeuroSearch Sweden AB   (Sweden)

Author keywords

6 OHDA; l DOPA induced dyskinesia; Locomotor sensitisation; Pridopidine; Rotation

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; LEVODOPA; OXIDOPAMINE; PNU 96391A; PRIDOPIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CENTRAL NERVOUS SYSTEM SENSITIZATION; DOPAMINE; DOPAMINE AGENTS; LEVODOPA; LOCOMOTION; MALE; OXIDOPAMINE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; TIME FACTORS;

EID: 84871928931     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.10.039     Document Type: Article

References (52)

1. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 16 2001 448 458 (Pubitemid 36041148)
2. A. Berthet, and E. Bezard Dopamine receptors and l-DOPA-induced dyskinesia Parkinsonism Relat. Disord. 15 4 2009 S8 S12
3. H.U. Bryant, D.L. Nelson, D. Button, H.W. Cole, M.B. Baez, V.L. Lucaites, D.B. Wainscott, C. Whitesitt, J. Reel, R. Simon, and G.A. Koppel A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines Life Sci. 59 1996 1259 1268 (Pubitemid 26322923)
4. K. Buck, and B. Ferger l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective Drug Discov. Today 15 2010 867 875
5. 2 dopamine receptors. J. Neural Transm. 118, 1523-1533.
6. D.B. Bylund, H.S. Blaxall, L.J. Iversen, M.G. Caron, R.J. Lefkowitz, and J.W. Lomasney Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning Mol. Pharmacol. 42 1992 1 5 (Pubitemid 23026120)
7. R.J. Carey Chronic l-DOPA treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance Brain Res. 568 1991 205 214
8. Carlsson, M.L., Burstein, E.S., Kloberg, A., Hansson, S., Schedwin, A., Nilsson, M., Rung, J.P., Carlsson I A., 2011. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors. J. Neural Transm. 118, 1511-1522.
9. A.R. Carta, L. Frau, A. Pinna, S. Pontis, N. Simola, N. Schintu, and M. Morelli Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat Synapse 62 2008 524 533 (Pubitemid 351794179)
10. M.A. Cenci, and C. Konradi Maladaptive striatal plasticity in l-DOPA-induced dyskinesia Prog. Brain Res. 183 2010 209 233
11. M.A. Cenci, C.S. Lee, and A. Bjorklund l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706 (Pubitemid 28362576)
12. J.G. de Yebenes, B. Landwehrmeyer, F. Squitieri, R. Reilmann, A. Rosser, R.A. Barker, C. Saft, M.K. Magnet, A. Sword, A. Rembratt, and J. Tedroff Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial Lancet Neurol. 10 2011 1049 1057
13. A. Dekundy, M. Lundblad, W. Danysz, and M.A. Cenci Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model Behav. Brain Res. 179 2007 76 89 (Pubitemid 46441485)
14. M.A. Delfino, A.V. Stefano, J.E. Ferrario, I.R. Taravini, M.G. Murer, and O.S. Gershanik Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias Behav. Brain Res. 152 2004 297 306 (Pubitemid 38757900)
15. T. Dyhring, E.O. Nielsen, C. Sonesson, F. Pettersson, J. Karlsson, P. Svensson, P. Christophersen, and N. Waters The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties Eur. J. Pharmacol. 628 2010 19 26
16. A. Ekesbo, P.E. Andren, L.M. Gunne, C. Sonesson, and J. Tedroff Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions Eur. J. Pharmacol. 389 2000 193 199 (Pubitemid 30109409)
17. A. Ekesbo, P.E. Andren, L.M. Gunne, and J. Tedroff (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease Neuroreport 8 1997 2567 2570 (Pubitemid 27308462)
18. G. Fabbrini, J.M. Brotchie, F. Grandas, M. Nomoto, and C.G. Goetz Levodopa-induced dyskinesias Mov. Disord. 22 2007 1379 1389 (quiz 1523) (Pubitemid 47280623)
19. S.J. Gil, C.H. Park, J.E. Lee, Y.K. Minn, and H.C. Koh Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats Brain Res. Bull. 84 2011 151 156
20. 2 dopamine receptor Proc. Natl. Acad. Sci. USA 86 1989 9762 9766 (Pubitemid 20030713)
21. 2 receptor ligand on l-DOPA-induced dyskinesias in MPTP monkeys Eur. J. Pharmacol. 412 2001 247 254 (Pubitemid 32144940)
22. B. Henry, A.R. Crossman, and J.M. Brotchie Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease Exp. Neurol. 151 1998 334 342 (Pubitemid 28285913)
23. M. Herrera-Marschitz, G. Arbuthnott, and U. Ungerstedt The rotational model and microdialysis: significance for dopamine signalling, clinical studies, and beyond Prog. Neurobiol. 90 2010 176 189
24. Huntington Study Group Unified Huntington's Disease Rating Scale: reliability and consistency Mov. Disord. 11 1996 136 142
25. P. Jenner Molecular mechanisms of l-DOPA-induced dyskinesia Nat. Rev. Neurosci. 9 2008 665 677
26. Kieburtz, K., on behalf of the HSG HART study investigators, 2011. A randomized, double-blind, placebo-controlled trial of ACR16 in Huntington's disease. Neurotherapeutics, 135.
27. S. Konitsiotis, and C. Tsironis Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon? Behav. Brain Res. 170 2006 337 341
28. 3 dopamine receptor selective compounds on l-DOPA-dependent abnormal involuntary movements in rats Neuropharmacology 56 2009 956 969
29. T.M. Kääriäinen, M. Käenmäki, M.M. Forsberg, N. Oinas, A. Tammimäki, and P.T. Männistö Unpredictable rotational responses to l-DOPA in the rat model of Parkinson's disease: the role of l-DOPA pharmacokinetics and striatal dopamine depletion Basic Clin. Pharmacol. Toxicol. 110 2012 162 170
30. Landwehrmeyer, B., Marder, K., Biilmann Rønn, B., Haglund, M. on behalf of the MermaiHD and HART study investigators, 2011. Effect of the dopaminergic stabilizer pridopidine on motor symptoms in Huntington's disease: a meta-analysis. Clin. Genet. 80, 48 (abstract 211).
31. E.L. Lane, and S.B. Dunnett Pre-treatment with dopamine agonists influence l-DOPA mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat Behav. Brain Res. 213 2010 66 72
32. H.S. Lindgren, D.R. Andersson, S. Lagerkvist, H. Nissbrandt, and M.A. Cenci l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem. 112 2010 1465 1476
33. 7) implicated in the regulation of mammalian circadian rhythms Neuron 11 1993 449 458 (Pubitemid 23287072)
34. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 2002 120 132 (Pubitemid 35478015)
35. C. Marin, E. Aguilar, G. Mengod, R. Cortes, and J.A. Obeso Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study Eur. J. Neurosci. 25 2007 259 269 (Pubitemid 46098896)
36. J.G. Mulheron, S.J. Casanas, J.M. Arthur, M.N. Garnovskaya, T.W. Gettys, and J.R. Raymond Human 5-HT1A receptor expressed in insect cells activates endogenous G(o)-like G protein(s) J. Biol. Chem. 269 1994 12954 12962
37. 2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat J. Pharmacol. Exp. Ther. 318 2006 810 818 (Pubitemid 44061255)
38. N.F. Nichols, M.G. Cimini, J.V. Haas, B.A. Staton, J. Tedroff, and K.A. Svensson PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease Neuropharmacology 43 2002 817 824 (Pubitemid 35217722)
39. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates second ed. 1986 Academic Press New York, NY
40. 2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16) J. Med. Chem. 53 2010 2510 2520
41. A. Pinna, S. Pontis, and M. Morelli Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment Behav. Brain Res. 171 2006 175 178 (Pubitemid 43728402)
42. H. Ponten, K. Sonniksen, T. Abrahamsson, N. Waters, B. Gustafsson, E. Hanse, and L. Groc Behavioral and neurochemical repercussions of hippocampal network activityblockade during the neonatal period Brain Res Dev Brain Res 155 1 2005 81 86 (Pubitemid 40342953)
43. H. Ponten, J. Kullingsjo, S. Lagerkvist, P. Martin, F. Pettersson, C. Sonesson, S. Waters, and N. Waters In vivo pharmacology of the dopaminergic stabilizer pridopidine Eur. J. Pharm. 644 2010 88 95
44. J.M. Senard, P. Mauriege, D. Daviaud, and H. Paris Alpha 2-adrenoceptor in HT29 human colon adenocarcinoma cell-line: study of [3H](-)-adrenaline binding Eur. J. Pharm. 162 1989 225 236 (Pubitemid 19083622)
45. N. Simola, M. Morelli, and A.R. Carta The 6-hydroxydopamine model of Parkinson's disease Neurotox. Res. 11 2007 151 167
46. O. Suchowersky, S. Reich, J. Perlmutter, T. Zesiewicz, G. Gronseth, and W.J. Weiner Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 66 2006 968 975 (Pubitemid 44044778)
47. 2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat Pharmacol. Biochem. Behav. 81 2005 887 893 (Pubitemid 41187824)
48. J. Tedroff, C. Sonesson, N. Waters, E.S. Waters, and A. Carlsson A pilot study of the novel dopamine stabiliser ACR16 in advanced Parkinsońs disease Mov. Disord. 19 2004 201
49. U. Ungerstedt, and G.W. Arbuthnott Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 24 1970 485 493
50. S. Varanese, J. Howard, and A. Di Rocco NMDA antagonist memantine improves levodopa-induced dyskinesias and on-off phenomena in Parkinson's disease Mov. Disord. 25 2010 508 510
51. S. Waters, D. Klamer, J. Tedroff, H. Ponten, C. Sonesson, B. Gronier, and N. Waters Pridopidine - effects on corticostriatal pathways controlling motor functions Clin. Genet. 80 2011 33 (Abstract 163)
52. P. Xia, H.S. Chen, D. Zhang, and S.A. Lipton Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses J. Neurosci. 30 2010 11246 11250